Form 4: CONMED Corp Executive Lalomia Acquires 26,895 Stock Options

Brent Lalomia, Vice President of QA and RA at CONMED Corp, reports the acquisition of 26,895 stock options on March 3, 2025, under the company's 2018 Long-Term Incentive Plan.

Summary

• Brent Lalomia, a Vice President at CONMED Corp, filed a Form 4 on March 5, 2025, reporting a transaction.
• On March 3, 2025, Lalomia acquired 26,895 stock options with an exercise price of $58.33.
• These options were granted under CONMED Corp's 2018 Long-Term Incentive Plan.
• The options vest in equal amounts over a five-year period and expire on March 3, 2035.
• Following the transaction, Lalomia directly owns 26,895 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally viewed neutrally to positively as it incentivizes management. The sentiment is therefore moderately positive.

Positives

• The grant of stock options aligns the executive's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and contribution to CONMED Corp.

Industry Context

Stock option grants are a common form of executive compensation in the medical device industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the medical device industry.
• Companies like Stryker, Medtronic, and Johnson & Johnson also utilize stock options as part of their long-term incentive plans for executives.
• The vesting schedule of five years is fairly standard for these types of grants.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
• The grant incentivizes the executive, potentially improving employee morale and productivity.

Key Dates